Background: French troops are exposed to tick-borne encephalitis (TBE) during their tours of duty in the Balkans. This disease, potentially serious because of its lethality and morbidity, has an effective vaccination. The epidemiological characteristics of TBE in the Balkans are not well known. Objective: In order to provide the French Department of Defence with arguments on the utility of vaccinating troops on missions in this area of Europe, we conducted a cost-benefit study. Design and setting: Through a decision analysis, we estimated the net benefit of a three-injection vaccination programme for all French military personnel in the Balkans versus no vaccination during a period from 2004 to 2014. We used a review of the literature to estimate the parameters necessary for the present study: the disease’s morbidity and death incidence rate; the disease’s sequelae; and the adverse effects of the vaccination. The initial hypothesis of the seroconversion rate of TBE in the Balkans was 834 per 100 000 person-years. Human life was valued in € (year 2004 values) by calculating the amounts paid by the French Department of Defence to military personnel in case of disabling sequelae and to their heirs in case of death.

Author names: 
Desjeux, G.
Galoisy-Guibal, L.
Colin, C.
Pharmacoeconomics 23(9) pp913-926.

Desjeux, G., L. Galoisy-Guibal and C. Colin (2005) “Cost-Benefit Analysis of Vaccination against Tick-Borne Encephalitis among French Troops” Pharmacoeconomics 23(9) pp913-926.

Geographical area: 
Policy areas considered: 
Decision-Support Tools: